Tampa biotech enrolls patients for Phase 2 trial
May 20, 2019 - More than 80 patients are enrolled for a Phase 2 clinical trial for AG013, the lead compound in a proposed treatment for oral mucositis from Oragenics (NYSE American: OGEN). There are 61 identified clinical test sites and 48 of them are actively enrolling patients, a news release from the Tampa biotechnology company said. In addition, the World Health Organization has provided Oragenics with the generic name of "dapatifagene navolactibac" for the AG013 compound.